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INTRODUCTION
 Pleomorphic xanthoastrocytoma (PXA) which 
was originally described in detail by Kepes et al. is an 
uncommon tumor that comprises of approximately 
1% of all astrocytic central nervous system (CNS) 
tumors.1-3 The most common presentation is seizure. 
Most of the PXAs are located supratentorially. 
Despite the ominous histologic features as marked 
cellular pleomorphism and lipidization, PXAs 
have a favorable prognosis and are classified as 
Grade II in the World Health Organization (WHO) 
classification.4,5 However few histologic features 
such as necrosis, significant nuclear atypia and 
many mitoses are indicative of a high grade tumor. 
The ideal is gross total resection, which offers an 
excellent prognosis.6-8
 Not a single comprehensive study has been done 
in Pakistan, which describes in detail, clinical and 
pathological characteristics of this tumor. In this 
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ABSTRACT
Background & Objective: Pleomorphic xanthoastrocytoma (PXA) is a rare primary WHO Grade II astrocytic 
tumor comprising of < 1% of all astrocytomas. It is generally benign and slow growing however disease 
progression and malignant transformation with anaplastic features have been infrequently reported. Our 
objective was to assess clinicopathological characteristics of this rare tumor at our center.
Methods: A retrospective study was conducted at Aga Khan University Hospital from January 1992 till 
January 2016. Data was entered on a proforma including patient demographics, clinical features, tumor 
location, histological features and follow-up, where available.
Results: Forty Seven cases of PXA were retrieved during the study period. The mean age was  23.8 years 
(SD=15.1) and median age was 19 years. The most frequent symptom was head ache (n=31). Male were 
more frequently affected (n=26). The commonest location was temporal lobe. On microscopic examination, 
tumors were pleomorphic without mitoses or necrosis, however two cases showed increased mitotic 
activity, and one case revealed associated gliosarcoma. Follow-up of only 29 cases was available for a 
period ranging between 2 and 184 months (85 months +/- 56 months). Outcome was good in 27 patients 
with the last follow up showing no radiographic or clinical evidence of tumor recurrence.
Conclusions: PXA is an infrequent tumor in our population also, with less than 50 cases identified in two 
decades study period. Due to its rarity and its bizarre histomorphology, it should be diagnosed correctly, as 
it has got better prognosis than other astrocytic tumors. 
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study, we describe the clinicopathologic features 
and prognostic factors of 47 patients with PXAs in 
Southern Pakistani population.
METHODS
 We reviewed the histopathology reports with 
pertinent information along with the slides of 
surgical specimens of all patients diagnosed as 
PXA in Histopathology department, Aga Khan 
University hospital from January 1992 till January 
2016 with total period of 24 years.
 Forty Seven consecutive patients were diagnosed 
with PXA based on the pathologic features 
described in the WHO classification of tumors of 
the central nervous system (2007). The PXAs that 
demonstrated increased mitotic activity (defined as 
5 or more mitoses per 10 high-power fields) with 
or without areas of necrosis were designated as 
“PXA with anaplastic features” according to WHO 
classification.
 The slides were reviewed and presence of necrosis, 
mitotic figures and Ki-67 were carefully evaluated 
by two pathologists (each having experience of more 
than three years post-fellowship). A comprehensive 
analysis was done on these patients regarding 
clinical and pathologic features at time of diagnosis 
as well as treatment and follow-up information, 
where available.
 All the details were recorded on a Performa. 
Percentages were calculated for the frequencies of 
numerical data. Four cases in which only reports 
were available and slides could not be obtained for 
review, from the record, were also excluded from 
the study. The cases reported as “astrocytoma with 
PXA-like features” were not included in the study.
 Departmental ethical clearance was obtained 
from the Department of Histopathology, AKUH. 
Institutional Ethical board review approval was not 
sought for, as no patient identifiable material was 
used in the study.
RESULTS
 Total 47 cases were retrieved from archives 
of department of histopathology, from January 
1992 to January 2016 during period of 24 years. 
Male:female ratio was 1.9: 1 and mean age was 
24.2 years. Median age was 19 and range was 
3 – 62 years. Apart from few patients, majority 
of the patients presented with tumors in the 
supratentorial hemispheres. In our study the most 
common location was temporal lobe followed by 
parietal lobe and frontal lobe. Other sites included 
lateral ventricles (n=3), cerebellum (n=2) and spinal 
cord (1 patient).  Symptoms at presentation were 
seizures only (n=28) and seizures with neurologic 
deficits (n=11) and headache only (n=8). Prominent 
fascicular pattern of the spindle cells was seen 
in most of the tumors but two tumors revealed 
spindle cells in haphazard pattern. Eosinophilic 
granular bodies (EGB) were also found frequently 
(n=45).  Mitotic counts ranged from 0 to 9/10 HPFs. 
five tumors contained mitoses above 5/10HPF and 
all of these showed necrosis also. Microvascular 
proliferation was present in two of these 5 cases. 
All of these five cases were diagnosed as PXA 
with Anaplastic features. Perivascular lymphocyte 
cuffing was identified in 40 cases (85%). One case 
showed malignant mesenchymal component also 
with diagnosis of Gliosarcoma with PXA. The Ki-67 
labeling index was >5% in five tumors. The tumor 
cells were positive for GFAP in all cases. S-100 
protein and Synaptophysin were present in 75% 
Fig.1: Hematoxylin and Eosin stained sections at 
medium power show pleomorphic cells with giant cells. 
(A&B). Spindling of the tumor cells 
(C) and Calcification (D) can also be seen.
Fig.2: Immunohistochemical stain Glial Fibrillary 
Acidic Protein [GFAP] (A) and Ki-67 
Proliferation  index [MIB-1] (B).
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of tumors, with a mean MIB-1/Ki-67 proliferative 
labeling index of 6%. Clinical features have been 
briefly outlined in Table-I.
 Follow-up of only 29 cases was available for 
a period ranging between 2 and 184 months (85 
months +/- 56 months). Outcome was good 
in 25 patients with the last follow up showing 
no radiographic or clinical evidence of tumor 
recurrence. Three patients died following 
progression of the disease; one at three months 
and two had recurrence at 15 and 23 months 
respectively. One more patient showed recurrence 
but was treated successfully.
DISCUSSION
 Gliomas are the largest group of primary central 
nervous system (CNS) tumors and comprise of variety 
of clinically and genetically distinct subclasses. 
Diffuse gliomas, which include astrocytomas, 
oligodendrogliomas and oligoastrocytomas are the 
most common type and are characterized by their 
infiltrative nature.1,9 They occur predominantly 
in adults. Pilocytic astrocytomas (WHO Grade-I) 
and Pleomorphic Xanthoastrocytomas (PXA) 
(WHO Grade-II) are pediatric neoplasms which are 
relatively circumscribed, offering the possibility of 
cure following complete resection.10-13
 Pleomorphic xanthoastrocytoma (PXA) is 
rare primary neoplasm of brain. Although 
histopathologic features suggest high grade tumor, 
PXA is a low-grade gliomas corresponding to WHO 
Grade-II and in spite of its pleomorphic appearance, 
it has a relatively good prognosis. It was added 
in the 1993 World Health Organization (WHO) 
classification of tumors of the CNS.14 Although PXA 
is an uncommon tumor, it has enthralled researchers 
worldwide. Many studies have been published 
since the description of the tumor. However most 
of the literature is from the West and very few cases 
from the Asian subcontinent and even fewer have 
been reported from Pakistan.13,14
 To date, this is the largest study to encompass the 
morphological details and frequency of PXA in our 
population in Southern Pakistan. As per Ahmed Z 
et al., 1110 cases of CNS neoplasms were reported 
over a six year period however, their recent data 
showed that 597 cases were reported in the year 2008 
alone. So the overall incidence has been on increase 
in the region. They reported PXA comprising 2.8 % 
of all CNS glial tumors.15 
 Advances in the knowledge of the natural history 
of PXA and itsprognosis have been hampered by its 
rarity. PXA has a relatively favorable prognosis than 
other infiltrative astrocytomas, with 30% recurrence 
rate and 75% to 80% overall survival rates following 
primary resection at 5 years of follow-up.5,7
 Pleomorphic Xanthoastrocytoma (PXA) is mostly 
seen in children and young adults.8,16 We also 
observed it in majority of children, however 10 
patients more than 40 years of age. The oldest patient 
with PXA was 62 years. Primary pleomorphic 
xanthoastrocytoma (PXA) of the spinal cord is a 
very rare slow growing tumor and very few cases 
have been reported to date. We encountered one 
spinal PXA also. 
 Histologically, PXA is characterized by spindle 
cells, multinucleated giant cells and foamy lipid-
laden xanthomatous cells. Mitosis and necrosis is 
commonly absent.17,18 Although PXA usually appears 
as a highly cellular astrocytic tumor composed of 
large, bipolar cells having pleomorphic appearance 
and spindled appearance with mononucleated and 
multinucleated giant cells. The nuclei are dark and 
lobulated and there is vacuolated glassy cytoplasm 
with the eosinophilic granular cell bodies and 
reticulin fibers in the background. The dense 
cellularity and pleomorphism raises a possibility of 
ganglioglioma and higher grade malignancies like 
glioblastoma, giant cell glioblastoma, gliosarcoma 
or even pleomorphic sarcoma. However necrosis is 
usually absent and mitoses are low. Few PXA can 
show increased mitoses with >5 / 10 High Power 
Field (HPF) along with necrosis which are termed 
as PXA with Anaplastic features. Less than one 
Pleomorphic Xanthoastrocytoma
Table-I: Salient Clinical features. (n=47).
Characteristics No. of cases (Percentage)
Age
<20 years 26 (55.3%)
>20 years 21 (44.7%)
Gender:
Male 32 (68.1%)
Female 15 (31.9%)
Location:
Supratentorial 44 (93.6%)
Infratentorial 3 (6.4%)
Presenting symptoms
Seizures only 28 (59.6)
Headache only 8 (17%)
>1 symptoms, 
 including seizures
11 (23.4%)
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third of the PXA shows anaplastic features and this 
has a bad prognosis. In our study, we found 5 (10%) 
anaplastic PXA, much less than 31% found in study 
by Ida CM et al.2
 This tumor develops chiefly at superficial cortical 
regions with or without partial involvement of 
leptomeninges and in the supracortical location, 
it occurs more preferably within the temporal 
lobes.19-21 We had significant number of tumor seen 
in 21 patients in temporal lobes, followed by parietal 
and frontal lobes. Interestingly intraventricular 
location was observed in three  cases, which is again 
an infrequent site for this neoplasm. No multifocal 
or multiple tumors were identified. 
 Immunohistochemical studies demonstrated 
diffuse positivity for Glial Fibrillary Acidic Protein 
(GFAP) and Vimentin in all the tumors. In literature 
it has been reported that about 70% of cases show 
Immunostain CD34 positivity. We also saw CD34 
positivity in 20 (76.9%) out of 26 cases, in which it 
was applied. 
 PXA associated with other tumors as collision 
tumors have also been rarely described. We received 
one case of PXA with gliosarcoma or we can word 
it as Gliosarcoma arising in PXA. Approximately 
40% of PXA are reported to recur within 10 years 
of primary resection. Upon recurrence, patients 
receive radiation therapy and conventional 
chemotherapeutics designed for high-grade 
gliomas. Genetic changes, that can be targeted in 
the recurrent tumors, for the treatment purposes. In 
our study three cases recurred but the recurrence 
factors could not be assessed in detail as surgical 
extent of resection details were not available. All 
the three cases were having Anaplastic features in 
the initial diagnosis. Giannini et al indicated the 
mitotic index as the most significant predictor of 
recurrence and survival in a multivariate analysis.3 
They suggested that the mitotic index >5 should be 
referred to as PXA with anaplastic features, as it 
denotes poor outcome group.20,22 Our findings also 
support this suggestion as all the recurrent cases 
had mitoses more than 5 / 10 HPF.
 Ki67 proliferation index is also usually very low 
and in our study, Ki67 was applied on 38 cases 
and out of these, five cases showed Ki67 >5%. 
The highest Ki67 proliferation was 20%, a case 
with anaplastic features, which also showed early 
recurrence. Treatment details were deficient apart 
from the recurrent cases, 2 of those had GTR and 
one had chemotherapy.
CONCLUSION
 PXA is rare tumor and we observed 1.6% PXAs 
of all Astrocytic tumors in Southern Pakistani 
population. In our population, it is not limited to 
pediatric population only and it can be diagnosed in 
adult population as well. Keeping in view, its good 
prognosis and different course of progression from 
other high grade gliomas, this should be entertained 
in the differential diagnosis of morphologically 
high grade entities by pathologists. 
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